BPC-157

BPC-157, short for Body Protection Compound-157, is a synthetic peptide composed of fifteen amino acids (sequence GEPPPGKPADDAGLV) that corresponds to a partial sequence of a body-protective protein discovered in human gastric juice ^[6]. Unlike many peptides, it is notably stable, resisting degradation in gastric acid, which is part of what has driven interest in it. It was investigated clinically under names such as PL-14736 as a candidate for inflammatory bowel disease and other conditions ^[6], and it has since become one of the most popular research and wellness peptides for tissue repair.

The scientific literature on BPC-157 is extensive but overwhelmingly preclinical, consisting largely of rodent studies from a single principal research group in Croatia and their collaborators. Across these studies it has consistently accelerated healing in a remarkable range of tissues, including tendon, ligament, skeletal muscle, bone, the gastrointestinal tract, and the nervous system, and it has shown protective effects on the gut-brain axis, blood vessels, and after various toxic or traumatic insults ^[1][5]. Reported actions include promotion of angiogenesis through vascular endothelial growth factor (VEGF), interaction with the nitric oxide system, upregulation of the growth hormone receptor, and reduction of inflammatory cytokines ^[2][3][4].

BPC-157 has no marketing approval from the US Food and Drug Administration or comparable agencies and is not an approved medicine; a 2025 systematic review found essentially only preclinical evidence plus a single small clinical report, and noted the peptide is banned in professional sport ^[2]. It is sold as a research chemical, typically as a lyophilized powder for reconstitution, and although preclinical safety studies have been reassuring, human safety and efficacy data remain very limited ^[2].

BPC-157 is a synthetic peptide marketed for healing and recovery, but despite widespread anecdotal use there are essentially no controlled human trials establishing its safety or efficacy; it is sold as a research chemical and is prohibited in sport. Reported effects are largely anecdotal and mild, such as injection-site reactions, while its long-term safety, drug interactions, and effects on angiogenesis (a theoretical concern for tumor growth) are not established in humans.

BPC-157 is a synthetic pentadecapeptide whose sequence corresponds to a fragment of Body Protection Compound (BPC), a protein identified in human gastric juice. It was discovered and has been characterized largely by Predrag Sikiric and colleagues at the University of Zagreb in Croatia, with work beginning in the early 1990s. Their group established the peptide's unusual stability in gastric juice and its wide-ranging cytoprotective and wound-healing activity across the gastrointestinal tract and musculoskeletal tissues. Over roughly three decades it has accumulated a large preclinical literature, yet it has never completed formal drug approval and remains investigational.

BPC-157 has earned an enthusiastic following in the recovery and sports-medicine community, prized for preclinical reports of faster and more complete healing in tissues that ordinarily mend poorly, such as tendon and ligament. Researchers highlight its remarkable safety margin in animals, where a lethal dose has not been reached, and its capacity to drive new blood-vessel growth and reroute blood flow around injuries. Its appeal is amplified by an unusually broad protective profile that spans gut, brain, and vascular tissue. In fairness, the human evidence remains thin, long-term safety is not established, and it is prohibited in competitive sport, so it is best regarded as a promising but still experimental peptide.